It is to provide a novel LXR² agonist useful as a preventative and/or therapeutic agent for atherosclerosis； arteriosclerosis such as those resulting from diabetes； dyslipidemia； hypercholesterolemia； lipid-related diseases； inflammatory diseases that are caused by inflammatory cytokines； skin diseases such as allergic skin diseases； diabetes； or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C-R 7 ； each X and Y independently show CH 2 , C=O, SO 2 , etc.； Z shows CH or N； each R 1 , R 2 and R 7 independently show a hydrogen atom, C 1-8 alkyl group, etc.； R 3 shows C 1-8 alkyl group； R 4 shows an optionally substituted C 6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group； R 5 and R 6 show a hydrogen atom, etc.； L shows a C 1-8 alkyl chain optionally substituted with an oxo group, etc.； and n shows any integer of 0 to 2.)
